All In Biotech

Drug Trial Radar · NCT01555164

A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Ranolazine When Added to Metformin in Subjects With Type 2 Diabetes Mellitus

Last checked: Nov 20, 2026Latest source record: Sep 23, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 442 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

442

Actual

Start

Jun 2012

Primary completion

Sep 2013

Study completion Oct 2013

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Mar 15, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to determine the effect of ranolazine when added to metformin on glycemic control in adults with type 2 diabetes mellitus (T2DM) who are inadequately controlled despite current treatment with stable metformin therapy in addition to diet and exercise.

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • RanolazineDrug

    Ranolazine tablet(s) administered orally

  • Placebo to match ranolazineDrug

    Placebo to match ranolazine for the duration of the study

  • MetforminDrug

    Metformin tablet(s) administered orally once daily

  • Placebo to match metforminDrug

    Placebo to match metformin for the duration of the study

  • DietBehavioral

    Participants are instructed to continue the diet regimen prescribed by their physician.

  • ExerciseBehavioral

    Participants are instructed to continue the exercise regimen prescribed by their physician.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24Time frame: Baseline; Week 24

Locations

146 sites in 11 countries. Site status is shown where the registry gives one.

  • Fundamental Research LLC

    Gulf Shores, Alabama

  • KLR Business Group DBA Arkansas Clinical Research

    Little Rock, Alaska

  • Radiant Research, Inc.

    Chandler, Arizona

  • Central Phoenix Medical Clinic

    Phoenix, Arizona

  • Clinical Research Advantage

    Tempe, Arizona

  • Desert Sun Clinical Research, LLC

    Tucson, Arizona

  • National Research Institute

    Los Angeles, California

  • Ritchken and First MD's

    San Diego, California

  • Clearview Medical Research, LLC

    Santa Clarita, California

  • Metabolic Institute of America

    Tarzana, California

  • University Clinical Investigators

    Tustin, California

  • Infosphere Clinical Research

    West Hills, California

  • Colorado Springs Health Partners

    Colorado Springs, Colorado

  • Boca Raton Clinical Research Associates, Inc.

    Boca Raton, Florida

  • MD Clinical Institute

    Hallandale, Florida

  • A G A Clinical Trials

    Hialeah, Florida

  • Baptist Diabetes Associates

    Miami, Florida

  • Florida Institute for Clinical Research LLC

    Orlando, Florida

  • Medical Research Group of Central Florida

    Sanford, Florida

  • Synergy Therapeutic Partners

    Atlanta, Georgia

  • Perimeter Institute for Clinical Research

    Atlanta, Georgia

  • Columbus Research Foundation

    Columbus, Georgia

  • Advanced Clinical Research

    Boise, Idaho

  • Choose To Lose

    Eagle, Idaho

  • Cedar-Crosse Research Center

    Chicago, Illinois

  • Alexandria Cardiology Clinic

    Alexandria, Louisiana

  • Covington Medical Care

    Mandeville, Louisiana

  • Clinical Trials Management, LLC

    Metairie, Louisiana

  • MD Medical Research

    Oxon Hill, Maryland

  • Bellevue Family Practice

    Bellevue, Nebraska

  • Clinical Research Advantage

    Henderson, Nevada

  • Albuquerque Clinical Trials, Inc.

    Albuquerque, New Mexico

  • University of New Mexico Health Sciences Center

    Albuquerque, New Mexico

  • PhysiqueMed Clinical Trials

    Greensboro, North Carolina

  • Clinical Trials of America Inc

    Hickory, North Carolina

  • University Medical Associates

    Huntersville, North Carolina

  • Northstate Clinical Research

    Lenoir, North Carolina

  • Carolina Research Center

    Shelby, North Carolina

  • Lillestol Research

    Fargo, North Dakota

  • Rapid Medical Research, Inc

    Cleveland, Ohio

Showing 40 of 146 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.